

(508) 893-8999

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of July 29, 2016, there were 34,313,005 shares of common stock, par value \$0.01 per share, outstanding.

Table of Contents

HARVARD BIOSCIENCE, INC.

FORM 10-Q

For the Quarter Ended June 30, 2016

INDEX

	Page
<u>PART I - FINANCIAL INFORMATION</u>	<u>3</u>
<u>Item 1. Financial Statements</u>	<u>3</u>
<u>Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015 (unaudited)</u>	<u>3</u>
<u>Consolidated Statements of Operations and Comprehensive (Loss) Income for the Three and Six Months Ended June 30, 2016 and 2015 (unaudited)</u>	<u>4</u>
<u>Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015 (unaudited)</u>	<u>5</u>
<u>Notes to Unaudited Consolidated Financial Statements</u>	<u>6</u>
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>20</u>
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	<u>32</u>
<u>Item 4. Controls and Procedures</u>	<u>33</u>
<u>PART II - OTHER INFORMATION</u>	<u>33</u>
<u>Item 1A. Risk Factors</u>	<u>33</u>
<u>Item 6. Exhibits</u>	<u>34</u>
<u>SIGNATURES</u>	<u>35</u>

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.****HARVARD BIOSCIENCE, INC.****CONSOLIDATED BALANCE SHEETS****(Unaudited, in thousands, except share and per share data)**

	June 30, 2016	December 31, 2015
<u>Assets</u>		
Current assets:		
Cash and cash equivalents	\$3,631	\$6,744
Accounts receivable, net of allowance for doubtful accounts of \$363 and \$310, respectively	16,347	17,547
Inventories	22,209	22,343
Deferred income tax assets - current	-	42
Other receivables and other assets	4,632	3,873
Total current assets	46,819	50,549
Property, plant and equipment, net	5,641	5,902
Deferred income tax assets - non-current	954	995
Amortizable intangible assets, net	19,617	20,872
Goodwill	39,735	40,357
Other indefinite lived intangible assets	1,225	1,223
Other assets	94	152
Total assets	\$114,085	\$120,050
Liabilities and Stockholders' Equity		
Current liabilities:		
Current portion, long-term debt	\$2,389	\$2,364
Accounts payable	6,577	8,782
Deferred revenue	913	752
Accrued income taxes	244	290
Accrued expenses	3,952	4,021
Deferred income tax liabilities - current	-	2,246
Other liabilities - current	775	868
Total current liabilities	14,850	19,323
Long-term debt, less current installments	13,774	16,369
Deferred income tax liabilities - non-current	6,070	3,775
Other long term liabilities	2,728	2,985
Total liabilities	37,422	42,452

Commitments and contingencies

Stockholders' equity:

Preferred stock, par value \$0.01 per share, 5,000,000 shares authorized	-	-
Common stock, par value \$0.01 per share, 80,000,000 shares authorized; 42,058,512 and 41,724,772 shares issued and 34,313,005 and 33,979,265 shares outstanding, respectively	417	416
Additional paid-in-capital	213,100	211,457
Accumulated deficit	(113,072)	(111,723)
Accumulated other comprehensive loss	(13,114)	(11,884)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	76,663	77,598
Total liabilities and stockholders' equity	\$114,085	\$120,050

See accompanying notes to unaudited consolidated financial statements.

Table of Contents**HARVARD BIOSCIENCE, INC.****CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME****(Unaudited, in thousands, except per share data)**

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Revenues	\$26,136	\$28,800	\$53,099	\$54,563
Cost of revenues (exclusive of items shown separately below)	14,461	16,205	28,479	30,490
Gross profit	11,675	12,595	24,620	24,073
Sales and marketing expenses	5,086	5,128	10,188	10,327
General and administrative expenses	5,236	4,922	11,184	9,753
Research and development expenses	1,502	1,714	2,927	3,462
Restructuring charges	1	54	12	111
Amortization of intangible assets	690	678	1,370	1,471
Total operating expenses	12,515	12,496	25,681	25,124
Operating (loss) income	(840)	99	(1,061)	(1,051)
Other income (expense):				
Foreign exchange	282	(134)	273	89
Interest expense	(180)	(215)	(344)	(437)
Interest income	-	3	1	4
Other expense, net	(29)	(180)	(79)	(796)
Other income (expense), net	73	(526)	(149)	(1,140)
Loss before income taxes	(767)	(427)	(1,210)	(2,191)
Income tax (benefit) expense	(54)	(776)	139	(1,139)
Net (loss) income	\$(713)	\$349	\$(1,349)	\$(1,052)
(Loss) earnings per share:				
Basic (loss) earnings per common share	\$(0.02)	\$0.01	\$(0.04)	\$(0.03)
Diluted (loss) earnings per common share	\$(0.02)	\$0.01	\$(0.04)	\$(0.03)
Weighted average common shares:				
Basic	34,127	33,569	34,070	33,240
Diluted	34,127	35,026	34,070	33,240
Comprehensive (loss) income:				
Net (loss) income	\$(713)	\$349	\$(1,349)	\$(1,052)

Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Foreign currency translation adjustments	(1,821)	1,760	(1,205)	(2,737)
Derivatives qualifying as hedges, net of tax:				
Loss on derivative instruments designated and qualifying as cash flow hedges	(12)	(12)	(48)	(71)
Amounts reclassified from accumulated other comprehensive loss to net loss	10	24	23	50
Total comprehensive (loss) income	\$(2,536)	\$2,121	\$(2,579)	\$(3,810)

See accompanying notes to unaudited consolidated financial statements.

Table of Contents**HARVARD BIOSCIENCE, INC.****CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited, in thousands)**

	Six Months Ended June 30,	
	2016	2015
Cash flows from operating activities:		
Net loss	\$(1,349)	\$(1,052)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock compensation expense	1,653	1,272
Depreciation	809	769
Loss on disposal of fixed assets	-	11
Non-cash restructuring credits	-	(64)
Amortization of catalog costs	6	8
Provision for allowance for doubtful accounts	44	3
Amortization of intangible assets	1,370	1,471
Amortization of deferred financing costs	56	30
Deferred income taxes	4	(1,027)
Changes in operating assets and liabilities:		
Decrease (increase) in accounts receivable	959	(2,136)
Increase in inventories	(95)	(1,242)
Increase in other receivables and other assets	(865)	(240)
(Decrease) increase in trade accounts payable	(2,459)	2,451
Decrease in accrued income taxes	(114)	(395)
Increase (decrease) in accrued expenses	13	(660)
Increase in deferred revenue	188	216
Decrease in other liabilities	(4)	(396)
Net cash provided by (used) in operating activities	216	(981)
Cash flows used in investing activities:		
Additions to property, plant and equipment	(402)	(1,640)
Additions to catalog costs	(10)	-
Proceeds from sales of property, plant and equipment	-	15
Acquisitions, net of cash acquired	-	(4,545)
Net cash used in investing activities	(412)	(6,170)
Cash flows provided by (used in) financing activities:		
Proceeds from issuance of debt	2,000	4,050
Repayments of debt	(4,625)	(4,850)
Payments of debt issuance costs	-	(32)
Net (taxes paid for) proceeds from issuance of common stock	(9)	1,864
Net cash (used in) provided by financing activities	(2,634)	1,032
Effect of exchange rate changes on cash	(283)	(613)

Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Decrease in cash and cash equivalents	(3,113)	(6,732)
Cash and cash equivalents at the beginning of period	6,744	14,134
Cash and cash equivalents at the end of period	\$3,631	\$7,402

Supplemental disclosures of cash flow information:

Cash paid for interest	\$312	\$427
Cash paid for income taxes, net of refunds	\$452	\$312

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

HARVARD BIOSCIENCE, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2015 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which was filed with the SEC on April 29, 2016.

In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2016, results of operations and comprehensive loss for the three and six months ended June 30, 2016 and 2015 and cash flows for the six months ended June 30, 2016 and 2015, as applicable, have been made. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Summary of Significant Accounting Policies

The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the SEC on April 29, 2016.

2. Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “*Revenue from Contracts with Customers*,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in the United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, *Simplifying Measurement of Inventory*. The update requires measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inventory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company.

In February 2016, the FASB issued ASU 2016-02, *Leases*, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. The Company is evaluating the impact of ASU 2016-02 on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, *Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting*, which simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2016 and early adoption is permitted. The Company is evaluating the impact of ASU 2016-09 on its consolidated financial statements.

Table of Contents

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326), Measurement of credit losses on Financial Instruments*. The update amends the FASB’s guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more timely recognition of such losses. The ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is evaluating the impact of ASU 2016-13 on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

In April 2015, the FASB issued ASU 2015-03, *Interest - Imputation of Interest - Simplifying the Presentation of Debt Issuance Costs*. Under this guidance, debt issuance costs related to a recognized debt liability should be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The provisions of this guidance are to be applied retrospectively and are effective for interim and annual periods beginning after December 15, 2015. The Company adopted this guidance during the six months ended June 30, 2016. The consolidated balance sheet as of December 31, 2015, included in these consolidated financial statements, reflects a restatement to reclassify unamortized deferred financing costs of approximately \$0.2 million from other long-term assets to long-term debt. For deferred financing costs paid to secure long-term debt, the Company made a policy election to present such costs as a direct deduction from the debt liability on the consolidated balance sheet.

In September 2015, the FASB issued ASU 2015-16, *Simplifying the Accounting for Measurement-Period Adjustments*. The update eliminates the requirement to retrospectively adjust financial statements for measurement-period adjustments that occur in periods after a business combination. Under the update, measurement-period adjustments are to be calculated as if they were known at the acquisition date, but are recognized in the reporting period in which they are determined. Additional disclosures are required about the impact on current-period earnings. ASU 2015-16 requires prospective application to adjustments of provisional amounts that occur after the effective date. The update was effective for fiscal years beginning after December 15, 2015. The Company adopted ASU 2015-16 on January 1, 2016. The adoption of ASU 2015-16 did not have a material impact on its consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, *Balance Sheet Classification of Deferred Taxes*. The update requires all deferred income taxes to be presented on the balance sheet as noncurrent. The new guidance is intended to simplify financial reporting by eliminating the requirement to classify deferred taxes between current and noncurrent. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted at the beginning of an interim or annual period. During the six months ended June 30, 2016, the Company early adopted the new guidance on a prospective basis and has presented all deferred tax assets and deferred tax liabilities as noncurrent in the consolidated balance sheet at June 30, 2016. Prior periods presented in the consolidated financial statements were not retrospectively adjusted.

3. Accumulated Other Comprehensive Loss

Changes in each component of accumulated other comprehensive loss, net of tax are as follows:

(in thousands)	Foreign currency translation adjustments	Derivatives qualifying as hedges	Defined benefit pension plans	Total
Balance at December 31, 2015	\$ (9,594)	\$ (10)	\$ (2,280)	\$ (11,884)
Other comprehensive loss before reclassifications	(1,205)	(48)	-	(1,253)
Amounts reclassified from AOCI	-	23	-	23
Other comprehensive loss	(1,205)	(25)	-	(1,230)
Balance at June 30, 2016	\$ (10,799)	\$ (35)	\$ (2,280)	\$ (13,114)

Table of Contents**4. Acquisitions**

The Company completed one acquisition during the six months ended June 30, 2015.

HEKA Elektronik

On January 8, 2015, the Company, through its wholly-owned Ealing Scientific Limited and Multi Channel Systems MCS GmbH (“MCS”) subsidiaries, acquired all of the issued and outstanding shares of HEKA Elektronik (“HEKA”) for approximately \$5.9 million, or \$4.5 million, net of cash acquired. Included in the acquisition of HEKA were: HEKA Elektronik Dr. Schulze GmbH, based in Lambrecht, Germany (“HEKA Germany”); HEKA Electronics Incorporated, based in Chester, Nova Scotia, Canada (“HEKA Canada”); and HEKA Instruments Incorporated, based in Bellmore, New York. The Company funded the acquisition from its existing cash balances.

HEKA is a developer, manufacturer and marketer of sophisticated electrophysiology instrumentation and software for biomedical and industrial research applications. This acquisition is complementary to the electrophysiology line currently offered by the Company’s wholly-owned Warner Instruments and MCS subsidiaries.

The aggregate purchase price for this acquisition was allocated to tangible and intangible assets acquired as follows:

	(in thousands)
Tangible assets	\$ 4,165
Liabilities assumed	(2,426)
Net assets	1,739
Goodwill and intangible assets:	
Goodwill	1,668
Trade name	774
Customer relationships	1,627
Developed technology	1,338
Non-compete agreements	27
Deferred tax liabilities	(1,245)
Total goodwill and intangible assets, net of tax	4,189
Acquisition purchase price	\$ 5,928

Goodwill recorded as a result of the acquisition of HEKA is not deductible for tax purposes.

At June 30, 2016, an immaterial correction was made to the allocation of the aggregate purchase price to the tangible and intangible assets acquired to increase both accrued liabilities and goodwill by \$50,000 as of June 30, 2016. This correction has been reflected in the table above.

The results of operations for HEKA have been included in the Company's consolidated financial statements from the date of acquisition.

Direct acquisition costs recorded in other expense, net in the Company's consolidated statements of operations were immaterial for both the three and six months ended June 30, 2016, respectively. Direct acquisition costs recorded in other expense, net in the Company's consolidated statements of operations were \$0.2 million and \$0.8 million for the three and six months ended June 30, 2015, respectively.

Table of Contents**5. Goodwill and Other Intangible Assets**

Intangible assets consist of the following:

	June 30, 2016 (in thousands)		December 31, 2015		Weighted Average Life	(a)
Amortizable intangible assets:	Gross	Accumulated Amortization	Gross	Accumulated Amortization		
Existing technology	\$ 15,731	\$ (11,807)	\$ 16,022	\$ (11,686)	7.2	Years
Trade names	7,666	(3,336)	7,636	(3,076)	8.5	Years
Distribution agreements/customer relationships	23,756	(12,506)	23,676	(11,849)	9.5	Years
Patents	222	(109)	245	(96)	2.7	Years
Total amortizable intangible assets	47,375	\$ (27,758)	47,579	\$ (26,707)		
Indefinite-lived intangible assets:						
Goodwill	39,735		40,357			
Other indefinite-lived intangible assets	1,225		1,223			
Total goodwill and other indefinite-lived intangible assets	40,960		41,580			
Total intangible assets, gross	\$ 88,335		\$ 89,159			

(a) Weighted average life as of June 30, 2016.

The change in the carrying amount of goodwill for the six months ended June 30, 2016 is as follows:

	(in thousands)
Balance at December 31, 2015	40,357
Adjustment to purchase price allocation of prior year acquisition	50
Effect of change in currency translation	(672)
Balance at June 30, 2016	\$ 39,735

Intangible asset amortization expense was \$0.7 million for both the three months ended June 30, 2016 and 2015. Intangible asset amortization expense was \$1.4 million and \$1.5 million for the six months ended June 30, 2016 and 2015, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be \$2.7 million for the year ending December 31, 2016, \$2.5 million for the year ending December 31, 2017, \$2.3 million for the year ending December 31, 2018, \$2.2 million for the year ending December 31, 2019 and \$2.2 million

for the year ending December 31, 2020.

6. Inventories

Inventories consist of the following:

	June 30, 2016	December 31, 2015
	(in thousands)	
Finished goods	\$ 10,093	\$ 10,957
Work in process	1,084	888
Raw materials	11,032	10,498
Total	\$ 22,209	\$ 22,343

Table of Contents**7. Property, Plant and Equipment**

Property, plant and equipment consist of the following:

	June 30, 2016	December 31, 2015
	(in thousands)	
Land, buildings and leasehold improvements	\$2,609	\$2,825
Machinery and equipment	10,523	10,131
Computer equipment and software	7,482	7,503
Furniture and fixtures	1,339	1,358
Automobiles	115	103
	22,068	21,920
Less: accumulated depreciation	(16,427)	(16,018)
Property, plant and equipment, net	\$5,641	\$5,902

8. Restructuring and Other Exit Costs***Q4 2015 Restructuring Plan***

The Company committed to a restructuring plan on October 27, 2015, which included eliminating certain positions made redundant as a result of its site consolidations, as well as a realignment of its commercial sales team. Payments related to this plan were made through the second quarter of 2016. Activity and liability balances related to these charges were as follows:

	Severance Costs (in thousands)
Restructuring balance at December 31, 2015	\$ 90
Cash payments	(90)
Restructuring balance at June 30, 2016	\$ -

Q2 2015 Restructuring Plan

Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

During the second quarter of 2015, management of the Company initiated a plan to consolidate the manufacturing operations of HEKA Canada to HEKA Germany in order to create organizational efficiencies. No further charges are expected to be incurred on this matter. At June 30, 2016, the Company has no remaining liability related to this plan on its balance sheet. Activity and liability balances related to these charges were as follows:

	Severance Costs (in thousands)
Restructuring charges	\$ 13
Cash payments	-
Restructuring balance at June 30, 2015	\$ 13

Table of Contents***Q1 2015 Restructuring Plan***

During the first quarter of 2015, the Company's management initiated a plan to relocate certain manufacturing operations in order to create organizational efficiencies and reduce operating expenses. The Q1 2015 restructuring plan included plans to consolidate the manufacturing operations of its Coulbourn subsidiary to its headquarters in Holliston, MA. Payments related to this plan are expected to be made through the third quarter of 2016. For the six months ended June 30, 2016, activity and liability balances related to these charges were as follows:

	Severance Costs	Other	Total
	(in thousands)		
Restructuring balance at December 31, 2015	\$11	\$ -	\$11
Restructuring charges	-	4	4
Cash payments	(8)	(4)	(12)
Restructuring balance at June 30, 2016	\$3	\$ -	\$3

For the six months ended June 30, 2015, activity and liability balances related to these charges were as follows:

	Severance Costs (in thousands)
Restructuring charges	88
Non-cash reversal of restructuring charges	(6)
Cash payments	-
Restructuring balance at June 30, 2015	\$ 82

2014 Restructuring Plan

During the fourth quarter of 2014, the Company's management initiated a plan to relocate certain distribution and manufacturing operations in order to create organizational efficiencies and reduce operating expenses. The 2014 restructuring plan included plans to relocate the distribution operations of the Company's Denville Scientific subsidiary from New Jersey to North Carolina, as well as consolidating the manufacturing operations of its Biochrom subsidiary to its headquarters in Holliston, MA. Payments related to this plan are expected to be made through the third quarter of 2016. For the six months ended June 30, 2016, activity and liability balances related to these charges were as follows:

	Severance Costs	Other	Total
	(in thousands)		
Restructuring balance at December 31, 2015	\$31	\$ -	\$31
Restructuring charges	-	8	8
Cash payments	-	(8)	(8)
Effect of change in currency translation	(3)	-	(3)
Restructuring balance at June 30, 2016	\$28	\$ -	\$28

For the six months ended June 30, 2015, activity and liability balances related to these charges were as follows:

	Severance Costs	Other	Total
	(in thousands)		
Restructuring balance at December 31, 2014	\$626	\$-	\$626
Restructuring charges	39	35	74
Non-cash reversal of restructuring charges	(58)	-	(58)
Cash payments	(129)	(35)	(164)
Effect of change in currency translation	3	-	3
Restructuring balance at June 30, 2015	\$481	\$-	\$481

Aggregate net restructuring charges for the three and six months ended June 30, 2016 and 2015 were as follows:

	Three Months Ended June 30, 2016	Six Months Ended June 30, 2015	Three Months Ended June 30, 2015	Six Months Ended June 30, 2015
	(in thousands)			
Restructuring charges	\$1	\$54	\$12	\$111

Table of Contents**9. Related Party Transactions**

As part of the acquisitions of MCS and Triangle BioSystems, Inc. (“TBSI”) in 2014, as well as HEKA in 2015, the Company signed lease agreements with the former owners of the acquired companies. The principals of such former owners of MCS, TBSI and HEKA were employees of the Company as of June 30, 2015, while the principals of such former owners of MCS and TBSI were employees of the Company as of June 30, 2016. Pursuant to a lease agreement, the Company incurred rent expense of approximately \$58,000 and \$10,000 to the former owners of MCS and TBSI, respectively, for the three months ended June 30, 2016. The Company incurred rent expense of approximately \$113,000 and \$21,000 to the former owners of MCS and TBSI, respectively, for both the six months ended June 30, 2016 and June 30, 2015. The Company incurred rent expense of approximately \$81,000 to the former owners of HEKA for the six months ended June 30, 2015. Pursuant to a lease agreement, the Company incurred rent expense of approximately \$58,000, \$11,000 and \$42,000 to the former owners of MCS, TBSI and HEKA, respectively, for the three months ended June 30, 2015.

10. Warranties

Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows:

	Beginning Balance (in thousands)	Payments	(Credits)	Additions/ (Credits)	Ending Balance
Year ended December 31, 2015	\$ 252	(81)	(24)		\$ 147
Six months ended June 30, 2016	\$ 147	(41)	87		\$ 193

11. Employee Benefit Plans

Certain of the Company’s subsidiaries in the United Kingdom, or UK, Harvard Apparatus Limited and Biochrom Limited, maintain contributory, defined benefit or defined contribution pension plans for substantially all of their employees. These defined benefit pension plans are closed to new employees, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows:

Three Months Ended June 30, 2016	Three Months Ended June 30, 2015	Six Months Ended June 30, 2016	Six Months Ended June 30, 2015
(in thousands)			

Components of net periodic benefit cost:

Interest cost	\$168	\$190	336	367
Expected return on plan assets	(181)	(179)	(362)	(345)
Net amortization loss	79	81	159	156
Net periodic benefit cost	\$66	\$92	\$133	\$178

For the three months ended June 30, 2016 and 2015, the Company contributed \$0.2 million, for both periods, to its defined benefit pension plans. For the six months ended June 30, 2016 and 2015, the Company contributed \$0.4 million, for both periods, to its defined benefit pension plans. The Company expects to contribute approximately \$0.4 million to its defined benefit pension plans during the remainder of 2016.

The Company had an underfunded pension liability of approximately \$2.6 million and \$2.8 million, as of June 30, 2016 and December 31, 2015, respectively, included in the other long term liabilities line item in the consolidated balance sheets.

Table of Contents**12. Leases**

The Company has noncancelable operating leases for office and warehouse space expiring at various dates through 2021 and thereafter. Rent expense, which is recorded on a straight-line basis, is estimated to be \$1.9 million for the year ended December 31, 2016. Rent expense was approximately \$0.5 million and \$0.4 million for the three months ended June 30, 2016 and 2015, respectively. Rent expense was approximately \$1.0 million and \$0.8 million for the six months ended June 30, 2016 and 2015, respectively.

Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at June 30, 2016, are as follows:

	Operating Leases (in thousands)
2017	\$ 1,711
2018	1,707
2019	1,600
2020	1,422
2021	1,210
Thereafter	3,552
Net minimum lease payments	\$ 11,202

13. Capital Stock*Common Stock*

On February 5, 2008, the Company's Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company's common stock to shareholders of record as of the close of business on February 6, 2008. Initially, these rights will not be exercisable and will trade with the shares of the Company's common stock. Under the Shareholder Rights Plan, the rights generally will become exercisable if a person becomes an "acquiring person" by acquiring 20% or more of the common stock of the Company or if a person commences a tender offer that could result in that person owning 20% or more of the common stock of the Company. If a person becomes an acquiring person, each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of preferred stock which are equivalent to shares of the Company's common stock having a value of twice the exercise price of the right. If the Company is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock having a value of twice the exercise price of the right.

Preferred Stock

The Company's Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of June 30, 2016, the Company had no preferred stock issued or outstanding.

Employee Stock Purchase Plan (as amended, the "ESPP")

In 2000, the Company approved the ESPP. Under this ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company's common stock. At the conclusion of the period, participating employees can purchase shares of the Company's common stock at 85% of the lower of the fair market value of the Company's common stock at the beginning or end of the period. Shares are issued under the ESPP for the six-month periods ending June 30 and December 31. Under this plan, 750,000 shares of common stock are authorized for issuance of which 683,364 shares were issued as of June 30, 2016. During the three months ended June 30, 2016 and 2015, the Company issued 39,353 shares and 26,181 shares, respectively, of the Company's common stock under the ESPP.

Table of Contents

Stock Option and Equity Incentive Plans

Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “Third A&R Plan”)

The Second Amendment to the Third A&R Plan (the “Amendment”) was adopted by the Board of Directors on April 3, 2015. Such Amendment was approved by the stockholders at the Company’s 2015 Annual Meeting of Stockholders. Pursuant to the Amendment, the aggregate number of shares authorized for issuance under the Third A&R Plan was increased by 2,500,000 shares to 17,508,929.

Restricted Stock Units with a Market Condition (the “Market Condition RSU’s”)

On August 3, 2015, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSU’s to members of the Company’s management team under the Third A&R Plan. The vesting of these Market Condition RSU’s is cliff-based and linked to the achievement of a relative total shareholder return of the Company’s common stock from August 3, 2015 to the earlier of (i) August 3, 2018 or (ii) upon a change of control (measured relative to the Russell 3000 index and based on the 20-day trading average price before each such date). As of June 30, 2016, the target number of these restricted stock units that may be earned is 182,150 shares; the maximum amount is 150% of the target number.

Stock-Based Payment Awards

The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, Market Condition RSU’s and employee stock purchases related to the ESPP.

Stock option and restricted stock unit activity under the Company’s Third A&R Plan for the six months ended June 30, 2016 was as follows:

Stock Options	Weighted Average Exercise	Restricted Stock Units	Restricted Stock Units Grant Date	Market Condition RSU's Market Grant Date
---------------	---------------------------------	---------------------------	---	---

Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

	Outstanding	Price	Outstanding	Fair Value	Condition RSU's Outstanding	Fair Value
Balance at December 31, 2015	5,022,186	\$ 3.85	313,559	\$ 5.29	185,538	\$ 4.81
Granted	28,000	3.24	941,190	2.93	-	-
Exercised	(338,532)	2.83	-	-	-	-
Vested (RSUs)	-	-	(251,320)	-	-	-
Cancelled / forfeited	(369,270)	3.79	(25,636)	4.07	(3,388)	4.81
Balance at June 30, 2016	4,342,384	\$ 3.93	977,793	\$ 3.20	182,150	\$ 4.81

The weighted average fair value of the options granted under the Third A&R Plan during the three months ended June 30, 2016 and 2015 was \$1.48 and \$2.08, respectively. The weighted average fair value of the options granted under the Third A&R Plan during the six months ended June 30, 2016 and 2015 was \$1.26 and \$2.21, respectively. The following assumptions were used to estimate the fair value, using the Black-Scholes option pricing model, of stock options granted during the three and six months ended June 30, 2016 and 2015:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2016	2015	2016	2015
Volatility	42.91 %	39.35 %	41.39 %	41.08 %
Risk-free interest rate	1.40 %	1.70 %	1.45 %	1.72 %
Expected holding period (in years)	5.16 years	5.28 years	5.27 years	5.52 years
Dividend yield	- %	- %	- %	- %

The Company used historical volatility to calculate the expected volatility for each grant as of the grant date. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company's stock options and Market Condition RSU's. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. The correlation coefficient, used to value the Market Condition RSU's, represents the way in which entities move in relation to the Russell 3000 index as a whole.

Table of Contents

Stock-based compensation expense related to stock options, restricted stock units, Market Condition RSU's and the ESPP for the three and six months ended June 30, 2016 and 2015 was allocated as follows:

	Three Months Ended June 30, 2016		Six Months Ended June 30, 2015	
	2016	2015	2016	2015
	(in thousands)			
Cost of revenues	\$ 16	\$ 15	\$ 27	\$ 36
Sales and marketing	141	107	242	194
General and administrative	713	548	1,335	997
Research and development	29	22	49	45
Total stock-based compensation	\$ 899	\$ 692	\$ 1,653	\$ 1,272

The Company did not capitalize any stock-based compensation.

Earnings per share

Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSU's into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended June 30,	
	2016	2015
Basic	34,127,131	33,569,180
Effect of assumed conversion of employee and director stock options, restricted	-	1,456,470

Target Annual Cash Bonus Opportunities

In May 2017, the Compensation Committee reviewed the target annual cash bonus opportunities for Named Executive Officers, including the Named Executive Officers, taking into consideration the competitive market data, its compensation consultant, the recommendations of our CEO and Chief Financial Officer (and our own target annual cash bonus opportunities), and the other factors described above in our Compensation Program. Target annual cash bonus opportunities were expressed as a percentage of an officer's base salary.

stock units
and Market
Condition
RSU's

Following this review, the Compensation Committee adjusted the target annual cash bonus opportunities for our executive officers to maintain the competitiveness of these amounts by increasing the target annual cash bonus opportunities from their fiscal 2017 levels. Mr. Gochee's target annual cash bonus opportunity increased from 45% to 50%, and Ms. Schulman's target annual cash bonus opportunity increased from 40% to 45%. Mr. Cirne's target total cash compensation in line with that of similarly positioned executive officers in the compensation peer group. Mr. Cirne's target annual cash bonus opportunity was maintained at 100%. Mr. Sachleben's target annual cash bonus opportunity was maintained at 60%.

The target annual cash bonus opportunities of the Named Executive Officers for purposes of the Compensation Committee's Opportunity were as follows:

Named Executive Officer	Fiscal 2017 Target Annual Cash Bonus Opportunity	Fiscal 2018 Target Annual Cash Bonus Opportunity (as a percentage of base salary)
Mr. Cirne	100%	100%
Mr. Sachleben	60%	60%
Mr. Gochee	45%	50%
Ms. Schulman	40%	45%

Table of Contents*Corporate Performance Objectives and Bonus Formula*

In May 2017, the Compensation Committee, after receiving input from our CEO and Chairman, selected annual recurring revenue (ARR) and non-GAAP operating income as the corporate performance measures for determining potential quarterly bonus payouts under the Fiscal 2018 Bonus Opportunity Plan. The Compensation Committee believed that these were appropriate corporate performance measures to use as they can be clear indicators of our successful operation of our business. For purposes of these payouts,

ARR, which was based on our net incremental annual recurring revenue, is calculated to measure our sales growth. For this purpose, we define ARR as the revenue we will receive from those customers over the following 12 months, without any increase or decrease in subscriptions.

Non-GAAP operating income, which was calculated as our GAAP loss from operations plus compensation expense, amortization of stock-based compensation capitalized in software development, amortization of purchased intangibles, lawsuit litigation expense and employer payroll taxes and incentive plans.

For each of these performance measures, the Compensation Committee established a target bonus payment schedule for each fiscal quarter, as well as the target weighting for each measure.

For ARR (70% weighting), payments were to be based on our actual ARR for a quarter divided by the ARR target level for the quarter, raised to the 1.5 power.

For non-GAAP operating income (30% weighting), payments were to be based on our actual non-GAAP operating income for a quarter divided by the non-GAAP operating income target level for the quarter. For the first three quarters of fiscal 2018:

Non-GAAP Operating Income as a Percentage of Target	Non-GAAP Operating Income Attainment Percentage
120% or more	40%
110% - <120%	35%
100% - <110%	30%
95% - <100%	25%
90% - <95%	20%
85% - <90%	15%
80% - <85%	10%
<80%	0%

For the fourth quarter of fiscal 2018:

Non-GAAP Operating Income as a Percentage of Target	Non-GAAP Operating Income Attainment Percentage
120% or more	40%
110% - <120%	35%
100% - <110%	30%
95% - <100%	15%
90% - <95%	0%

The Fiscal 2018 Cash Bonus Opportunity also contained a profitability bonus provision, incremental 5% would be added to the non-GAAP operating income component in the event that the non-GAAP operating income was greater than zero in any of the first, second or third fiscal quarters. The profit bonus was paid out for the third fiscal quarter.

Table of Contents

The target levels established for each of these performance measures were intended to represent a significant increase in performance for each part of our executive officers and, therefore, were set at levels the Compensation Committee believed would be difficult to achieve and for which average or below-average performance would result in smaller bonuses. The aggregate target levels for these performance measures represented a significant increase in performance for each part of our executive officers and, therefore, were set at levels the Compensation Committee believed would be difficult to achieve and for which average or below-average performance would result in smaller bonuses.

Using these aggregate target levels, the Compensation Committee established quarterly performance measures that were consistent with our past experience, our existing new business pipeline, our understanding of our current business environment and competitive factors. During fiscal 2018, the Compensation Committee recommended, and the Board approved, adjustments for the second, third and fourth quarters to reflect business expectations, but the targets remained at levels the Compensation Committee believed would be difficult to achieve.

The amount that each executive officer, including our Named Executive Officers, was eligible to receive was based on our actual achievement with respect to each of these performance measures. The maximum amount of the quarterly bonuses awarded to each executive officer for fiscal 2018 could have been more than the annual cash bonus opportunity depending on whether and what extent we achieved our corporate performance. The Compensation Committee retains the ability, in its sole discretion, to increase or decrease the amount of any bonus to any executive officer regardless of the actual performance against these measures. A performance bonus is paid for any year, and the amount of any such bonus, is within the discretion of the Compensation Committee.

Fiscal 2018 Bonus Decisions

Our actual performance against the relevant target level for each corporate performance measure, as well as the determination of the amount to be received by each executive officer, were determined by the Compensation Committee after taking into consideration the recommendations of our Compensation Committee (other than with respect to their own quarterly bonuses) and subject to the discretion of the Compensation Committee to adjust any payment based on corporate financial or other considerations. The Compensation Committee may make any discretionary adjustments to the quarterly bonuses paid to the Named Executive Officers.

Table of Contents

The following table provides information regarding the quarterly bonus awards earned by our executive officers during fiscal 2018:

Named Executive Officer	Performance Period	Target Quarterly Bonus	Target Performance Level
Mr. Cirne	First Quarter	\$ 78,750	
	Second Quarter	\$ 78,750	
	Third Quarter	\$ 78,750	
	Fourth Quarter	\$ 78,750	
	Total 2018	\$ 315,000	
Mr. Sachleben	First Quarter	\$ 51,000	
	Second Quarter	\$ 51,000	
	Third Quarter	\$ 51,000	
	Fourth Quarter	\$ 51,000	
	Total 2018	\$ 204,000	
Mr. Gochee	First Quarter	\$ 41,875	
	Second Quarter	\$ 41,875	
	Third Quarter	\$ 41,875	
	Fourth Quarter	\$ 41,875	
	Total 2018	\$ 167,500	
Ms. Schulman	First Quarter	\$ 34,875	
	Second Quarter	\$ 34,875	
	Third Quarter	\$ 34,875	
	Fourth Quarter	\$ 34,875	
	Total 2018	\$ 104,625	

The aggregate cash bonus payments earned by the Named Executive Officers for fiscal 2018 are shown in the Fiscal 2018 Summary Compensation Table below.

Long-Term Incentive Compensation

The Compensation Committee believes that long-term incentive compensation is an effective way to align the interests of our executive officers, including the Named Executive Officers, to increase stockholder value. Long-term incentive compensation provides a meaningful reward for appreciation in our stock price and long-term value creation, and it encourages our executive officers to remain employed with us. Our equity award grant practices are designed to reflect a balance

our desire to motivate, retain, and reward executive talent;

our need to remain competitive in recruiting; and

effectively managing the dilution of stockholders' interests.

We use equity awards in the form of options to purchase shares of our common stock and are currently not using cash to settle for shares of our common stock to deliver the annual long-term incentive compensation awards to our executive officers, including the Named Executive Officers, and to address special situations from time to time. The Compensation Committee believes that stock options, when granted with an exercise price equal to the fair market value of our common stock on the date of grant, provide an appropriate long-term incentive for our executive officers, since the options reward them only to the extent that our stock price increases and they realize value following their grant date. The Compensation Committee believes that RSUs provide a more immediate reward to executive officers and reward them for long-term stock price appreciation while

Table of Contents

at the same time providing some value to the recipient even if the market price of our common stock declines. The Compensation Committee also believes that RSU awards helps us to manage dilution to our shareholders and to provide greater transparency and predictability to our executive officers regarding the full range of compensation opportunities.

In determining the appropriate mix of stock options and RSU awards, the Compensation Committee considers the current stock and other equity holdings of each executive officer and competitive market data. The Compensation Committee also considers the compensation provided to executive officers by the companies in our compensation peer group and the mix that would provide the appropriate incentives while staying competitive in our market.

As discussed above, the Compensation Committee determines the amount of long-term incentive compensation for executive officers as part of its annual compensation review and after taking into consideration the market analysis prepared by its compensation consultant, the recommendations of our CEO (excluding the amount of long-term incentive compensation), the outstanding equity holdings of each executive officer, the impact of the proposed awards on our earnings, our burn rate in relation to the median practice of the companies in our compensation peer group, our overhang in relation to the median practice of the companies in our compensation peer group, and the other factors described above in Governance of Executive Compensation.

In May 2017, after considering the factors described above, the Compensation Committee granted stock options to executive officers, including the Named Executive Officers, options to purchase shares of our common stock. With the exception of our CEO, RSU awards that may be settled for shares of our common stock. The Compensation Committee also reviewed Mr. Cirne's target total direct compensation, including the amount of long-term incentive compensation, as well as an analysis against the compensation arrangements at the companies in the compensation peer group and a detailed equity and other compensation analysis. Mr. Cirne received an option grant that will begin vesting when his fiscal 2015 option grant is fully vested. The Compensation Committee believes the compensation more in line with market practices.

The equity awards granted to the Named Executive Officers for fiscal 2018, which were determined based on the market price of our common stock as reported on The New York Stock Exchange immediately preceding May 15, 2017, were as follows:

Named Executive Officer	Annual Options to Purchase Shares of our Common Stock (number of shares)	Annual RSU Awards for Shares of our Common Stock (number of shares)
Mr. Cirne	125,000	
Mr. Sachleben	55,662(2)	24,637
Mr. Gochee	41,746(2)	18,477
Ms. Schulman	13,916(2)	6,167

- (1) The number of shares of our common stock subject to the RSU awards was determined based on the market price for our common stock as reported on The New York Stock Exchange immediately preceding May 15, 2017.

- (2) The number of shares of our common stock subject to the options was determined by use to calculate fair market value of stock options in our financial statements, using price for our common stock as reported on The New York Stock Exchange for the 30 days immediately preceding May 15, 2017, except that no provision was made for estimating the effect of service-based vesting requirements.

The shares of our common stock subject to the stock options for our Named Executive Officer will vest and become exercisable with respect to 1/48th of the total number of shares subject to the options in equal increments each month following the vesting commencement date of April 1, 2017, subject to the Named Executive Officer's continued employment through each such vesting date. The shares of our

Table of Contents

common stock subject to the RSU awards vest with respect to 1/16th of the total number vesting in equal increments each fiscal quarter following the vesting commencement date of the Named Executive Officer's continued employment through each such vesting date. The option vest and become exercisable in 12 equal monthly installments beginning on April 1, 2018.

The above equity awards granted to the Named Executive Officers in fiscal 2018 are reported in the Summary Compensation Table and the Fiscal 2018 Grants of Plan-Based Awards Table.

401(k) Plan, ESPP, Welfare, and Health Benefits

We maintain a 401(k) plan, which is intended to be qualified under Section 401(a) of the Code and a related trust intended to be tax exempt under Section 501(a) of the Code. Our 401(k) plan provides all full-time employees with an opportunity to save for retirement on a tax-advantaged basis. Under the plan, all full-time employees may defer eligible compensation subject to applicable annual contribution limits. The plan is a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are accumulated for employees until distributed from the plan. Employees are immediately and fully vested in their contributions. We initiated an employer matching contribution program on employee contributions in the second quarter of 2018. We match 50% of employee contributions, up to \$4,000 in matching contributions per employee per year, and such matching contributions are immediately and fully vested.

We also offer our employees, including our executive officers, the opportunity to purchase our common stock at a discount under our ESPP. Pursuant to the ESPP, all eligible employees, including our executive officers, may allocate up to 15% of their base salary to purchase our stock at a 15% discount to the market price, subject to specified limits.

In addition, we provide other benefits to our executive officers, including the Named Executive Officers, on a basis as all of our full-time employees. These benefits include, but are not limited to, medical, dental, vision benefits, group life, and accidental death and dismemberment insurance plans.

We design our employee benefits programs to be affordable and competitive in relation to the market and compliant with applicable laws and practices. We adjust our employee benefits programs periodically based on monitoring of applicable laws and practices and the competitive market.

Perquisites and Other Personal Benefits

Currently, we do not view perquisites or other personal benefits as a significant component of our compensation program. Accordingly, we do not provide perquisites or other personal benefits to our executive officers, including the Named Executive Officers, except in situations where we believe it is appropriate to reward the performance of his or her duties, to make our executive officers more efficient and effective, or for retention purposes. During fiscal 2018, none of the Named Executive Officers received perquisites or other personal benefits that were, in the aggregate, \$10,000 or more for each individual.

In the future, we may provide perquisites or other personal benefits in limited circumstances as described in the preceding paragraph. All future practices with respect to perquisites or other personal benefits will be subject to periodic review by the Compensation Committee.

Pension Benefits

Other than with respect to our 401(k) plan, our U.S. employees, including the Named Executive Officers, do not participate in any plan that provides for retirement payments and benefits, or payments and benefits provided primarily following retirement.

Table of Contents

Nonqualified Deferred Compensation

During fiscal 2018, our U.S. employees, including the Named Executive Officers, did not receive any amounts with respect to, any defined contribution or other plan sponsored by us that provide for nonqualified compensation on a basis that is not tax-qualified.

Severance and Change-in-Control Arrangements

We have entered into post-employment compensation arrangements with each of our Named Executive Officers described in more detail in *Potential Payments upon Termination or Change in Control*.

We believe that having in place reasonable and competitive post-employment compensation arrangements are important to attracting and retaining highly-qualified executive officers. Our post-employment compensation arrangements are designed to provide reasonable compensation to executive officers who leave the Company to facilitate their transition to new employment. Further, we seek to mitigate any potential future disputes or litigation by requiring a departing executive officer to sign a separation agreement acceptable to us as a condition to receiving post-employment compensation payments or benefits.

In determining payment and benefit levels under the various circumstances covered by our post-employment compensation arrangements, the Compensation Committee has drawn a distinction between voluntary terminations of employment, terminations of employment for cause, and involuntary terminations of employment with or not involving a change in control of the Company. Payment in the latter circumstances is considered appropriate in light of the benefits to us described above, as well as the likelihood that the executive officer is due, at least in part, to circumstances not within his or her control. In contrast, we believe that payment is not appropriate in the event of a voluntary resignation or a termination of employment for cause. These payments often reflect either an affirmative decision by the executive officer to end his or her relationship with us or his or her performance.

The post-employment compensation arrangements with our Named Executive Officers are designed to provide benefits in the event of an involuntary termination of employment in connection with a change in control of the Company. We believe that these arrangements are designed to align the interests of management with those of our stockholders considering the long-term future for the Company. The primary purpose of these arrangements is to provide senior executive officers focused on pursuing all corporate transaction activity that is in the best interests of our stockholders regardless of whether those transactions may result in their own job loss. Reasonable severance payments and benefits should serve the interests of both the executive officer and our stockholders.

All payments and benefits in the event of a change in control of the Company are payable to the executive officer subsequent loss of employment by an executive officer (a so-called "double-trigger" arrangement). In addition to acceleration of vesting of outstanding equity awards, we use this double-trigger arrangement to provide retention power following a change in control of the Company and to avoid windfalls. In the event of a change in control, vesting accelerated automatically as a result of the transaction.

We did not provide any executive officer, including any Named Executive Officer, with a gross-up or reimbursement payment for any tax liability that the executive officer may owe as a result of a change in control of the Company under Section 280G or 4999 during fiscal 2018, and we have not agreed and are not otherwise obligated to provide any executive officer with such a gross-up or other reimbursement.

The Compensation Committee does not consider specific amounts payable under these p
arrangements when establishing annual compensation. It does believe, however, that the
to offer compensation packages that are competitive.

Table of Contents

For information on the estimate of the potential payments and benefits payable under our compensation arrangements with our Named Executive Officers as of the end of fiscal 2018 upon Termination or Change in Control, see below.

Other Compensation Policies and Practices

Equity Awards Grant Policy

The Compensation Committee has delegated authority to our CEO and Chief Financial Officer to grant equity awards to our employees (other than our executive officers) and consultants, subject to the terms and conditions of our equity award plans. Such awards may be granted on a monthly basis to newly-hired employees and consultants, to our employees and consultants in connection with a promotion or in recognition of their contributions to the Company, to our employees and consultants as part of our annual equity merit program, and to existing employees and consultants as spot awards. In each instance, the policy provides for a limitation on the maximum size of the award, the number of options to purchase shares of our common stock, the exercise price of such options must be at least the market value of our common stock on the date of grant.

Stock Ownership Policy

At this time, we have not adopted a stock ownership policy with respect to our executive officers due to the significant existing equity holdings of our CEO. As detailed in Security Ownership and Management, the beneficial ownership of our current executive officers was as of June 1, 2018.

Compensation Recovery Policy

At this time, we have not adopted a compensation recovery, or clawback, policy for our executive officers. We will comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and will adopt a compensation recovery policy to the extent required by law once the SEC adopts final rules on this subject.

Policy Prohibiting Hedging and Pledging of Our Equity Securities

Our Insider Trading Policy, among other things, prohibits our employees, including our directors, and members of our Board from engaging in short sales, hedging of stock ownership positions, or trading in derivative securities relating to our common stock. In addition, our executive officers and any person required to comply with the blackout periods or pre-clearance requirements under our Insider Trading Policy are prohibited from pledging Company securities as collateral for loans, and may not hold margin accounts.

Tax and Accounting Considerations

Deductibility of Executive Compensation

Generally, Section 162(m) of the Code disallows a federal income tax deduction for public company compensation in excess of \$1 million paid for any fiscal year to certain executive officers.

Companies that recently completed an initial offering of their equity securities to the public are subject to a transition period before the deduction limit of Section 162(m) becomes applicable to corporations with plans and arrangements that were in effect at the time of their initial public offering. This transition period may extend until the Annual Meeting, unless it is terminated earlier under the post-initial public offering rules or under the amendments to Section 162(m) that were part of the Tax Reform Act of 2017 effective for taxable years beginning after December 31, 2017.

Table of Contents

Taxation of Parachute Payments and Deferred Compensation

Sections 280G and 4999 of the Code provide that executive officers and members of our equity interests and certain other service providers may be subject to an excise tax if they, in connection with a change in control of the Company that exceeds certain prescribed limits, a successor, may forfeit a deduction on the amounts subject to this additional tax. Section 4999, or 409A of the Code during fiscal 2018, and we have not agreed and are not otherwise providing any executive officer with such a gross-up or other reimbursement.

We did not provide any executive officer, including any Named Executive Officer, with a reimbursement payment for any tax liability that he or she might owe as a result of the application of Sections 280G, 4999, or 409A of the Code during fiscal 2018, and we have not agreed and are not otherwise providing any executive officer with such a gross-up or other reimbursement.

Accounting for Stock-Based Compensation

We follow the Financial Accounting Standard Board Accounting Standards Codification (FASB ASC) Topic 718 for our stock-based compensation awards. FASB ASC Topic 718 requires us to measure the fair value of all share-based payment awards made to our employees and members of our Board, including restricted stock awards, shares of our common stock and other stock awards, based on the grant date fair value. The fair value is performed for accounting purposes and reported in the executive compensation tables. FASB ASC Topic 718 also requires us to recognize the compensation cost of our stock-based awards in our income statements over the period that a recipient is required to render service in exchange for the award.

FASB ASC Topic 718 also requires us to recognize the compensation cost of our stock-based awards in our income statements over the period that a recipient is required to render service in exchange for the award.

COMPENSATION COMMITTEE REPORT⁽¹⁾

The Compensation Committee has reviewed and discussed with management the Compensation Committee Report (the CD&A) contained in this proxy statement. Based on this review and discussion, the Compensation Committee has recommended to the Board that the CD&A be included in this proxy statement and the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2018.

Peter Fenton

Sohaib Abbasi

James Tolonen

⁽¹⁾ The material in this report is not soliciting material, is furnished to, but not deemed to be incorporated by reference in any filing of the Company under the Securities Act of 1933, other than the Company's Annual Report on Form 10-K, where it shall be deemed to be incorporated by reference before or after the date hereof and irrespective of any general incorporation language.

ANALYSIS OF RISKS PRESENTED BY OUR COMPENSATION POLICIES AND PROGRAMS

Our compensation programs consist of both fixed and variable compensation. The fixed portion is designed to provide a steady income regardless of our stock price performance so that our employees, do not focus exclusively on stock price performance to the detriment of other important objectives. The variable (annual cash bonus and equity) portions are designed to reward corporate performance.

Table of Contents

We have reviewed our compensation policies and practices for employees generally, as well as for our officers, and concluded that these policies and practices do not create risks that are reasonably likely to have a material adverse effect on us. In reaching this conclusion, we assessed our executive and broad-based incentive programs to determine if any of them created undesired or excessive risks of a material nature. The risks we identified included:

a review of our compensation policies and practices for employees generally;

identification of the risks that could result from such policies and practices; and

analysis of the potential risks against our business strategy and objectives. In reaching this conclusion, we note the following factors that we believe may reduce the risk of excessive risk-taking:

our overall compensation levels are competitive with the market;

our compensation policies and practices appropriately balance fixed pay versus variable pay, short-term incentives versus long-term incentives;

although our annual incentive plans provide for variability of payout, we believe the risks associated with such plans are controlled or mitigated by one or more of the following factors:

the performance measures being multi-dimensional, thereby increasing the range of outcomes for which incentives are paid;

the performance measures and related target levels being generally aligned with our business objectives and being quantitative in nature;

the use of sliding payout scales where appropriate; and

the ability of management and/or the Compensation Committee to exercise discretion in determining payouts; and

although the equity awards granted to our employees could motivate them to, among other things, increase our short-term stock price rather than the creation of long-term stockholders.

potential risks are controlled or mitigated by one or more of the following:

use of a combination of equity vehicles;

use of multi-year vesting schedules for our time-based equity awards; and

our prohibition on engaging in hedging transactions in our securities for our executive officers.

We believe that the variable elements of compensation represent a sufficient percentage to motivate employees, including our executive officers, to produce positive short-term and long-term results, while the fixed element is sufficient to ensure that our employees are not encouraged to take excessive risks in doing so.

The Compensation Committee conducts an annual review of our compensation-related programs and believes that our compensation programs do not encourage excessive or inappropriate risk-taking and that the risk of our compensation programs encourage is not reasonably likely to have a material adverse effect on us.

Table of Contents**SUMMARY COMPENSATION TABLE**

The following table sets forth certain summary information for the year indicated with respect to the compensation earned by each of our Named Executive Officers.

Fiscal 2018 Summary Compensation Table

Name and Principal Position	Year	Salary (\$)(1)	Bonus (\$)	Stock Awards (\$)(2)	Option Awards (\$)(3)	Non-Equity Incentive Compensation (\$)
Lewis Cirne <i>Chief Executive Officer</i>	2018	315,000			2,515,150	33,000
	2017	315,000				34,000
	2016	300,000				18,000
Mark Sachleben <i>Chief Financial Officer and Corporate Secretary</i>	2018	340,000		1,098,362	1,098,367	214,000
	2017	325,000		758,888	252,964	211,000
	2016	300,000		766,767	768,649	138,000
James Gochee <i>Chief Product Officer</i>	2018	335,000		823,794	823,765	176,000
	2017	320,000		607,115	202,376	156,000
	2016	285,800		482,510	483,402	94,000
Robin Schulman(6) <i>Former Vice President, General Counsel, and Corporate Secretary</i>	2018	272,442		274,613	274,602	106,000
	2017	295,000		379,444	126,482	128,000
	2016	260,000		325,004	325,811	59,000

- (1) The dollar amounts reported in this column represent base salary earned during the indicated fiscal year. For more information regarding base salaries in fiscal 2018, see Compensation Discussion and Analysis, Compensation Elements Base Salary above.
- (2) The dollar amounts reported in this column reflect the aggregate grant date fair value of restricted stock awards granted during the indicated fiscal year computed in accordance with ASC 718 and excluding forfeitures. The grant date fair value of each RSU award is measured based on the closing price of our common stock on the date of grant. These amounts do not necessarily correspond to the cash bonus that may be recognized by the Named Executive Officers.
- (3) The dollar amounts reported in this column reflect the aggregate grant date fair value of stock options awarded during the indicated fiscal year. These amounts have been calculated in accordance with ASC 718, using the Black-Scholes option-pricing model and excluding the effect of dividends. Assumptions used in the calculation of these amounts are included in our Annual Report on Form 10-K for the indicated fiscal year as filed with the SEC. These amounts do not necessarily correspond to the cash bonus value recognized or that may be recognized by the Named Executive Officers.
- (4) The dollar amounts reported in this column represent the cash bonus earned under the Annual Cash Bonus Opportunity for the indicated fiscal year. For more information, see Compensation Discussion and Analysis, Compensation Elements Annual Cash Bonus Opportunity above.
- (5)

The dollar amounts reported in this column include Company matching contribution plan of up to \$4,000 in a calendar year. Prior to fiscal 2018, the Company provided \$2,000 in a calendar year. In fiscal 2016, a one-time discretionary additional amount was contributed to the 401(k) accounts of all U.S. employees who contributed at least one dollar to their 401(k) accounts in 2015.

- (6) Ms. Schulman resigned as our Vice President, General Counsel and Corporate Secretary in 2018.
- (7) Includes \$8,490 paid to Ms. Schulman following her resignation pursuant to her consulting agreement with Ms. Schulman for more information.

Table of Contents**GRANTS OF PLAN BASED AWARDS**

The following table provides information with regard to each grant of plan-based award to an Officer under any plan during the fiscal year ended March 31, 2018.

Fiscal 2018 Grants of Plan Based Awards Table

Name	Award Type	Grant Date	Approval Date	Estimated	Estimated	Other
				Possible Payouts Under Non-Equity Incentive Plan Awards Target (\$)(1)	Possible Payouts Under Non-Equity Incentive Plan Awards Maximum (\$)(1)	Stock Awards Number of Stock or Units (#)(2)
Lewis Cirne	Annual Stock Option	5/15/2017	5/5/2017			
	Annual RSU Grant					
	Annual Bonus			315,000	630,000	
Mark Sachleben	Annual Stock Option	5/15/2017	5/5/2017			
	Annual RSU Grant	5/15/2017	5/5/2017			24,600
	Annual Bonus			204,000	408,000	
James Gochee	Annual Stock Option	5/15/2017	5/5/2017			
	Annual RSU Grant	5/15/2017	5/5/2017			18,400
	Annual Bonus			167,500	335,000	
Robin Schulman	Annual Stock Option	5/15/2017	5/5/2017			
	Annual RSU Grant	5/15/2017	5/5/2017			6,100
	Annual Bonus			139,500	279,000	

(1) These columns set forth the target and maximum bonus amounts for each Named Executive Officer for the fiscal year ended March 31, 2018 under the Fiscal 2018 Bonus Opportunity. There are no thresholds for bonus awards for any individual officer established under the performance bonus plan. Target bonuses were set as a percentage of each Named Executive Officer's base salary earned for the fiscal year ended March 31, 2018. Target bonuses were set at 200% of target bonus. The dollar value of the actual bonus award earned for each Named Executive Officer in 2018 for each Named Executive Officer is set forth in the Fiscal 2018 Summary Compensation Table. As such, the amounts set forth in these columns do not represent either additional or alternative bonus amounts for the Named Executive Officers for the year ended March 31, 2018. For a description of the Fiscal 2018 Bonus Opportunity, see Compensation Discussion and Analysis Compensation Elements Fiscal 2018 Bonus Opportunity above.

(2) The RSU awards were granted under the 2014 Equity Incentive Plan (the 2014 Plan). The RSU awards vest with respect to 1/16th of the total number of shares of common stock in equal increments each quarter following the grant date, subject to the Named Executive Officer's continued employment with the Company.

Table of Contents

- (4) Stock options were granted with an exercise price equal to 100% of the fair market value of our common stock on the date of grant, which was \$44.58 per share for the annual grants that were granted based on the closing market price of our common stock on the grant date.
- (5) The dollar amounts in this column represent the grant date fair value of each stock option, if applicable, granted to the Named Executive Officers in fiscal 2018. These amounts were calculated in accordance with ASC 718. The grant date fair value of each stock option is calculated using a Black-Scholes option-pricing model and excluding the effect of estimated forfeitures. Assumptions used in the calculation of these amounts are included in our Annual Report on Form 10-K for the indicated fiscal year. These amounts do not necessarily correspond to the actual value recognized or that may be recognized by us.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

The following table provides information with regard to each outstanding equity award held by our Named Executive Officers at March 31, 2018.

Fiscal 2018 Outstanding Equity Awards at Fiscal Year End

Name	Vesting Commencement Date	Option Awards		Option Exercise Price (\$)	Option Expiration Date
		Number of Securities Underlying Unexercised Options (#)	Number of Securities Underlying Unexercised Options (#)(1)		
Lewis Cirne	4/1/2014	560,083	154,917(3)	16.93	5/14/2020
	4/1/2019		125,000(4)	44.58	5/14/2020
Mark Sachleben	4/1/2012	250,000		3.19	6/5/2020
	12/15/2014	57,281	13,219(5)	23.00	12/10/2020
	5/15/2015	21,776	30,447(6)	30.71	5/14/2020
	4/1/2016	10,231	11,121(7)	25.86	5/15/2020
	4/1/2017	12,755	42,907(7)	44.58	5/14/2020
	12/15/2014				
	5/15/2015				
James Gochee	5/1/2012	55,000		3.19	6/5/2020
	12/15/2014	20,566	5,972(11)	23.00	12/10/2020
	5/15/2015	9,230	12,906(6)	30.71	5/14/2020
	8/15/2015	6,486	3,558(12)	34.39	8/16/2020
	4/1/2016	8,184	8,898(7)	25.86	5/15/2020
	4/1/2017	9,566	32,180(7)	44.58	5/14/2020
	12/15/2014				
	5/15/2015				
	8/15/2015				
	5/15/2016				

	5/15/2017				
Robin Schulman	12/15/2014	1,837	(15)	23.00	12/10/20
	5/15/2015	369	(15)	30.71	5/14/20
	4/1/2017	870	(15)	44.58	5/14/20

- (1) In addition to the specific vesting schedule for each stock option award, each unvested award shall be subject to the general terms of the 2014 Plan and 2008 Equity Incentive Plan ("2008 Plan"), as amended from time to time.

Table of Contents

- including the potential for future vesting acceleration described below under the heading "Termination or Change in Control."
- (2) The market values of the RSU awards that have not vested are calculated by multiplying the market values of the underlying RSU awards shown in the table by \$74.12, the closing price of our common stock on March 29, 2018, the last trading day of fiscal 2018.
 - (3) The shares subject to the stock option vest over a five-year period, with 1/60th of the shares vesting on each monthly anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (4) The shares subject to the option vest over a one-year period, with 1/12th of the shares vesting on each monthly anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (5) The shares subject to the stock option vest over a four-year period, with 1/4th of the shares vesting on each first four anniversaries of the vesting commencement date, subject to continued service with us through each vesting date.
 - (6) The shares subject to the stock option vest over a four-year period, with 10% of the shares vesting on each first anniversary of the vesting commencement date, 15% vesting in monthly installments over the second year, 15% vesting in monthly installments over the year thereafter, and 55% vesting in monthly installments over the third year, subject to continued service with us through each vesting date.
 - (7) The shares subject to the stock option vest over a four-year period, with 1/48th of the shares vesting on each monthly anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (8) The shares subject to the RSU award vest over a four-year period, with 1/4th of the shares vesting on each first four anniversaries of the vesting commencement date], subject to continued service with us through each vesting date.
 - (9) The shares subject to the RSU award vest over a four-year period, with 10% of the shares vesting on each first anniversary of the vesting commencement date, 15% vesting in quarterly installments over the second year, 15% vesting in quarterly installments over the third year, and 55% vesting in quarterly installments over the fourth year, subject to continued service with us through each vesting date.
 - (10) The shares subject to the RSU award vest over a four-year period, with 1/16th of the shares vesting on each first anniversary following the vesting commencement date, subject to continued service with us through each vesting date.
 - (11) The shares subject to the stock option vest over a four-year period, with 20% of the shares vesting on each first anniversary of the vesting commencement date, 25% vesting on the two-year anniversary of the vesting commencement date, 25% of the shares vesting on the three-year anniversary of the vesting commencement date, and 30% vesting on the four-year anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (12) The shares subject to the stock option vest over a four-year period, with 1/4th of the shares vesting on each first anniversary of the vesting commencement date and thereafter 1/48th of the shares vesting on each monthly anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (13) The shares subject to the RSU award vest over a four-year period, with 20% of the shares vesting on each first anniversary of the vesting commencement date, 25% vesting on the two-year anniversary of the vesting commencement date, 25% of the shares vesting on the three-year anniversary of the vesting commencement date, and 30% vesting on the four-year anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (14) The shares subject to the RSU award vest over a four-year period, with 1/4th of the shares vesting on each first anniversary of the vesting commencement date and thereafter 1/16th of the shares vesting on each monthly anniversary of the vesting commencement date, subject to continued service with us through each vesting date.
 - (15) Ms. Schulman's equity awards ceased vesting on March 16, 2018 upon the completion of her consulting services to us. See Consulting Agreement with Ms. Schulman for more information.

Table of Contents**OPTION EXERCISES AND STOCK VESTED**

The following table provides information on RSU awards that vested and stock options exercised during the fiscal year ended March 31, 2018, the number of shares of our common stock acquired upon vesting or exercise and the value realized on exercise or vesting, as described below, for the Named Executive Officers during the fiscal year ended March 31, 2018.

Fiscal 2018 Option Exercises and Stock Vested Table

Name	Option Awards		Number of Shares Acquired on Vesting
	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise (\$)(1)	
Lewis Cirne			
Mark Sachleben			25,000
James Gochee	63,876	2,516,461	15,000
Robin Schulman	29,889	956,169	10,000

- (1) The value realized on exercise is based on the difference between the closing price of our common stock on the date of exercise and the applicable exercise price of those options, and the amounts received by the Named Executive Officers as a result of the option exercise.
- (2) The value realized on vesting is based on the number of shares underlying the RSU awards granted to the Named Executive Officers by the closing market price of the shares of our common stock on the vesting date.

EQUITY COMPENSATION ARRANGEMENTS

Since our initial public offering, we have granted stock options and RSU awards to our Executive Officers, under the 2014 Plan. Until our initial public offering, we granted stock options to our employees, including the Named Executive Officers, under the 2008 Plan. For more information on our equity compensation program and decisions regarding the grants of equity awards in fiscal 2018 to our Executive Officers, see *Compensation Discussion and Analysis – Compensation Elements – Equity Compensation* above. The following is a brief summary of the material terms of each of our equity compensation plans.

2008 Equity Incentive Plan

The Board adopted and our stockholders subsequently approved our 2008 Plan in February 2008, most recently amended by the Board and approved by our stockholders in November 2014, at the time the underwriting agreement for our initial public offering was executed and no longer in effect. Our 2008 Plan after it terminated.

Equity Awards

Outstanding awards granted under the 2008 Plan remain subject to its terms and applicable provisions until the awards are exercised or otherwise terminate or are forfeited by their terms. Only stock options and RSU awards have been granted under our 2008 Plan.

Plan Administration

The Board has delegated its authority to administer the 2008 Plan to the Compensation Committee. Under the terms of the 2008 Plan, the Board or the Compensation Committee determined the recipients, the types of stock awards to be granted, and the terms and conditions of the stock awards under the 2008 Plan, including the period of their exercisability and vesting.

Table of Contents

Corporate Transactions; Change in Control

Our 2008 Plan provides that in the event of a corporate transaction, any surviving or acquired (or its parent company) may assume or continue any part or all of the stock awards outstanding under the 2008 Plan or may substitute similar stock awards; and any reacquisition or repurchase rights held by us or our successor (or the successor's parent company). In connection with a corporate transaction, stock awards not assumed in connection with a corporate transaction will not be accelerated and will not be exercised (if applicable) prior to the effective time of the corporate transaction, except that the repurchase rights held by us will not terminate and may continue to be exercised notwithstanding the corporate transaction. Notwithstanding the foregoing, in the event a stock award will terminate if not exercised by the effective time of a corporate transaction, the Board may provide, in its sole discretion, that the holder of such award may not exercise such stock award but will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A) the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (B) any exercise price payable by such holder upon exercise.

Under the 2008 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of substantially all of our assets, (2) a sale or other disposition of at least 90% of our outstanding common stock, consolidation, or similar transaction following which we are not the surviving corporation, or (3) a consolidation, or similar transaction following which we are the surviving corporation but the percentage of stock outstanding immediately prior to such transaction are converted or exchanged into common stock as a result of such transaction.

Our 2008 Plan provides that in the event of a change in control, stock awards may be subject to acceleration of vesting and exercisability as may be provided in the stock award agreement covering such awards, or in any agreement with us, but in the absence of such provision, no such acceleration will occur.

Under our 2008 Plan, a change in control is generally (1) the acquisition by a person or persons of a majority of the combined voting power other than by merger, consolidation, or similar transaction; (2) a merger, consolidation, or similar transaction immediately after which our stockholders cease to own or exercise a majority of the combined voting power of the surviving entity; (3) a complete dissolution or liquidation of the corporation or its liquidation into a parent corporation; (4) a consummated sale, lease, or exclusive license of a substantial portion of substantially all of our assets; or (5) when a majority of the Board becomes comprised of individuals who were not on the Board on the date of adoption of the 2008 Plan (the Incumbent Board), provided that the appointment or election (or nomination for election) of any new Board member was approved by a majority vote of the members of the Incumbent Board then still in office, such new member shall not be considered a member of the Incumbent Board.

2014 Equity Incentive Plan

The Board adopted, and our stockholders approved, our 2014 Plan, which became effective upon the execution of an agreement for our initial public offering was executed.

Stock Awards

Our 2014 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, RSU awards, other stock awards, and performance awards that may include cash or other property, which may be granted to employees, including our Named Executive Officers.

RSU awards have been granted under our 2014 Plan.

Plan Administration

The Board has delegated its authority to administer the 2014 Plan to the Compensation Committee. Under the terms of our 2014 Plan, the Compensation Committee has the authority to determine the terms

Table of Contents

including recipients, the exercise, purchase, or strike price of stock awards, if any, the number of shares of common stock awarded, the vesting schedule of the stock award, the fair market value of a share of our common stock, the vesting schedule of the stock award, together with any vesting acceleration, and the form of consideration, if any, payable upon the exercise of the stock award, and the terms of the award agreements.

Corporate Transactions; Change in Control

Our 2014 Plan provides that in the event of certain corporate transactions, the following provisions shall apply to all outstanding stock awards, unless otherwise provided in a stock award agreement or any other agreement between us and a participant, or unless otherwise expressly provided by the Board at the time of the transaction:

the surviving or acquiring corporation (or its parent) may assume, continue, or modify the terms of the stock awards for outstanding stock awards under the 2014 Plan and any reacquisition or repurchase rights held by us will be assigned to the surviving or acquiring corporation (or its parent);

to the extent that outstanding stock awards are not so assumed, continued, or modified, the terms of the stock awards shall apply, exercisability of any such stock awards will not be accelerated and will terminate if not exercised (if applicable) at or prior to the effective time of such transaction; and that any reacquisition or repurchase rights held by us will not terminate and modify the terms of the stock awards notwithstanding the corporate transaction; or

to the extent a stock award will terminate if not exercised prior to the effective time of such transaction, the Board may provide that the holder of the stock award may not exercise the stock award and may receive a payment, in such form as may be determined by the Board, equal in value to the value of the property the participant would have received upon exercise of the stock award, less the price payable by such holder in connection with such exercise.

Under our 2014 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of substantially all of our assets, (2) a sale or other disposition of at least 90% of our outstanding common stock, consolidation, or similar transaction following which we are not the surviving corporation, (3) a consolidation, or similar transaction following which we are the surviving corporation but the terms of the stock awards outstanding immediately prior to such transaction are converted or exchanged into the terms of the stock awards of the surviving corporation.

A stock award may be subject to additional acceleration of vesting and exercisability upon the occurrence of a corporate transaction as may be provided in the stock award agreement for such stock award or in any other agreement between us and a participant, but in the absence of such a provision, no such acceleration will occur.

Under our 2014 Plan, a change in control is generally (1) the acquisition by a person or a group of persons of a combined voting power other than by merger, consolidation, or similar transaction; (2) a merger, consolidation, or similar transaction immediately after which our stockholders cease to constitute a majority of the combined voting power of the surviving entity; (3) a consummated sale, lease, or exclusive license of all or substantially of our assets; (4) a complete dissolution or liquidation of the Company; (5) the conversion of the Company into a parent corporation; or (6) when a majority of the Board becomes comprised of individuals who were not members of the Incumbent Board, provided, however, that if the appointment or election (or nomination) of the new Board is approved by a majority of the Incumbent Board.

Board member was approved or recommended by a majority vote of the members of the office, such new member will be considered as a member of the Incumbent Board.

2014 Employee Stock Purchase Plan

Additional long-term equity incentives are provided through our ESPP, which became e underwriting agreement for our initial public offering was executed. Our ESPP is intend

Table of Contents

employee stock purchase plan within the meaning of section 423 of the Code. Our executive officers, including Executive Officers, may have to satisfy one or more of the following service requirements to be eligible for the ESPP, as determined by the administrator: (i) customary employment for more than 20 hours per week for five months per fiscal year, or (ii) continuous employment for a minimum period of time. An employee may not be granted rights to purchase stock under our ESPP if such employee would own stock possessing 5% or more of the total combined voting power or value of the outstanding shares of the Company, or if the employee would own rights to purchase stock under our ESPP that would accrue at a rate that exceeds \$25,000 per year for each fiscal year that the rights remain outstanding.

The ESPP is implemented through a series of offerings of purchase rights to eligible employees. The administrator may specify offerings with a duration of not more than 27 months, and may specify shorter durations for each offering. Each offering will have one or more purchase dates on which our shares of common stock are purchased for employees participating in the offering. Unless otherwise determined by the administrator, the shares of stock are purchased for accounts of employees participating in our ESPP at a price per share of (a) 85% of the fair market value of a share of common stock on the first date of an offering and (b) the fair market value of a share of our common stock on the date of purchase.

In the event of a corporate transaction, a successor corporation may assume, continue, or substitute for the purchase right. If the successor corporation does not assume, continue, or substitute for the purchase right, the offering in progress will be shortened and the participants' accumulated contributions will be paid out within 10 business days prior to the effective date of the corporate transaction.

Under our ESPP, a corporate transaction is generally the consummation of (1) a sale or other disposition of substantially all of our assets, (2) a sale or other disposition of at least 90% of our outstanding shares of common stock, consolidation, or similar transaction following which we are not the surviving corporation, or (3) a consolidation, or similar transaction following which we are the surviving corporation but the shares of common stock outstanding immediately prior to such transaction are converted or exchanged into shares of another class of stock.

EMPLOYMENT ARRANGEMENTS

We have entered into written employment offer letters with certain of our executive officers, including Named Executive Officers other than our CEO.

In filling our executive positions, our Board or the Compensation Committee, as applicable, has had a need to develop competitive compensation packages to attract qualified candidates in a competitive market. At the same time, our Board or the Compensation Committee, as applicable, was sensitive to the need to align our executive officers into the executive compensation structure that we were seeking to develop, taking into account competitive and internal equity considerations.

Each of these employment offer letters provides for at will employment and sets forth the terms and conditions of employment arrangements for the executive officer, including an initial base salary, an annual cash bonus, and a target bonus. In the case of Mr. Sachleben's offer letter, though he is eligible to, and does, participate in our ESPP, the offer letter does not include an equity award recommendation. In addition, each of these employment offer letters also provides for terms related to vacation and participation in our employee benefit plans.

These letters also set forth the rights and responsibilities of each party in the event of a termination of employment, including following a change in control of the Company. For each of the Named Executive Officers, the offer letter also

post-employment compensation terms have been superseded by the change-in-control a

Table of Contents

severance agreements described in more detail in Severance and Change-in-Control B upon Termination or Change in Control below.

Mr. Cirne. As a founder, Mr. Cirne did not join us pursuant to an offer letter or any other understanding regarding his employment. We currently have no employment agreement and currently do not anticipate entering into one in the future. Mr. Cirne is an at-will emp

Mr. Sachleben. Mr. Sachleben is a party to an employment offer letter with us dated Feb he agreed to serve as our Chief Financial Officer. This employment offer letter provided \$160,000, which has been subsequently increased. Under his employment offer letter, M option to purchase 1,225,000 shares of our common stock at an exercise price of \$0.06 p over a four-year period.

Mr. Gochee. Mr. Gochee is a party to an employment offer letter with us dated April 16 agreed to serve as our Vice President of Engineering. This employment offer letter prov \$140,000 and a target annual bonus opportunity of \$30,000, which, in each case, has bee Under his employment offer letter, Mr. Gochee was granted an option to purchase 360,0 at an exercise price of \$0.06 per share, with vesting to occur over a four-year period.

Ms. Schulman. Ms. Schulman was a party to an employment offer letter with us dated N which she agreed to serve as our Vice President and General Counsel. This employment initial base salary of \$250,000 and a target annual bonus opportunity of \$50,000, which, subsequently increased. Effective February 16, 2018, Ms. Schulman resigned as our Vic and Corporate Secretary.

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

Change-in-Control and Severance Agreements

In December 2014, we entered into change-in-control and severance agreements (the P with Messrs. Cirne, Sachleben, and Gochee. In June 2016, Ms. Schulman also entered in Agreement. Because Ms. Schulman resigned as our Vice President, General Counsel and February 16, 2018, she was not entitled to compensation pursuant to her Post-Employment included in the discussion below.

The Post-Employment Agreements provide for payments and benefits upon certain term including a termination of employment in connection with or following a change in cont Post-Employment Agreement was originally in effect for three years from the date such after which each agreement may be renewed by the mutual agreement of the parties ther Agreements were amended in December 2017 to extend the term of such agreements to

Under the Post-Employment Agreements, the Named Executive Officers may receive pa connection with or within 12 months following a change in control of the Company upo termination of employment by us without cause (other than as a result of death or disabi employment for good reason, and for terminations of employment not in connection wit Company upon his or her involuntary termination of employment by us without cause (disability). Under the Post-Employment Agreements, payment and benefit levels are bas officers in higher positions generally receiving greater payments and benefits. In all case

benefits is subject to the executive officer executing a release and waiver of claims in fa

Table of Contents

For a qualifying termination of employment not in connection with a change in control of the Company, the payments and benefits consist of:

a salary continuation payment determined as a specified number of months of base salary;

continuation (or reimbursement) of health benefit premiums for that same period. For our CEO who is in Tier 1, the salary and benefit continuation period is 12 months, and for Mr. Sachleben and Mr. Gochee, who are in Tier 2, the salary and benefit continuation period is six months.

For a qualifying termination of employment in connection with or within 12 months after a change in control of the Company, the payments and benefits consist of:

a lump-sum cash payment determined as a specified number of months of base salary;

continuation (or reimbursement) of health benefit premiums for the number of months specified in the applicable Post-Employment Agreement; and a lump-sum cash payment; and

accelerated vesting of all outstanding equity awards then held by the executive officer. For our CEO who is in Tier 1, the cash lump-sum payment is equal to 18 months of base salary, with 12 months of benefit continuation, and for Mr. Sachleben and Mr. Gochee, who are in Tier 2, the cash lump-sum payment is equal to 12 months of base salary, with 12 months of benefit continuation.

Under the Post-Employment Agreements, the term "change in control" has the same meaning as in the Company's Amended and Restated Certificate of Incorporation. The term "cause" means the executive officer's (i) willful failure substantially to perform his or her duties to us or deliberate violation of our policies; (ii) commission of any act of fraud, embezzlement, or willful misconduct that has caused or is reasonably expected to result in material injury to the Company; or (iii) disclosure by the executive officer of any proprietary information or trade secrets of our Company. The executive officer owes an obligation of nondisclosure as a result of his relationship with the Company, and the executive officer is bound by his obligations under any written agreement or covenant with us.

Under the Post-Employment Agreements, the term "good reason" means the executive officer's termination of employment following the occurrence of any of the following without the executive officer's consent: (i) a material reduction in job duties, responsibilities, or authority inconsistent with the executive officer's position as provided, however, that any such reduction or change after a change in control will not constitute a "good reason" if the executive officer retains reasonably comparable duties, position, and responsibilities with the successor entity following a change in control; (ii) a material reduction of the executive officer's salary, representing a reduction of more than 10% of the executive officer's then-current base salary, except that a general salary level reduction in the salary level of all of our executive officers by the same percentage will not constitute such a material salary reduction; (iii) the relocation of the executive officer's principal place of employment to a place that increases the executive officer's commute time by more than 50 miles as compared to the executive officer's then-current principal place of employment.

relocation; (iv) any material breach by us of the Post-Employment Agreement or any other agreement between us and the executive officer; or (v) the failure by any successor to our company to assume the executive officer's Post-Employment Agreement; provided, that (a) the executive officer gives written notice of resignation on the basis of the resignation for good reason within 30 days after the date on which we give written notice to the executive officer of our affirmative decision to take an action set forth in clause (i), (ii), (iii), (iv) or (v); (b) the executive officer resigns on such basis for the good reason resignation within 30 days after receipt of the executive officer's written notice; or (c) the executive officer terminates his employment within 30 days following the expiration of the Post-Employment Agreement.

If the total value of the payments and benefits payable to an executive officer in the event of a change in control of the Company in connection with a change in control of the Company would exceed the dollar amount of the executive officer's annual salary for the year ending on the date of the change in control, the Company will pay to the executive officer the excess amount.

Table of Contents

Section 280G of the Code with respect to excess parachute payments, we will pay either the full amount or a reduced amount, whichever results in the greater after-tax benefit to the executive or

Consulting Agreement with Ms. Schulman

Simultaneously with her resignation on February 16, 2018, we entered into a consulting agreement pursuant to which she served in an advisory capacity regarding transition matters until March 16, 2018. Ms. Schulman was paid on an hourly basis for the hours actually worked at a rate equivalent to her prior salary on the date of her final date of employment with us. Ms. Schulman also continued vesting in her equity awards through March 16, 2018.

Potential Payments Upon Termination or Change in Control as of March 31, 2018

The table below sets forth the amount of compensation payable to each Named Executive Officer upon termination of employment without cause or resignation for good reason or upon termination of employment without cause or good reason in connection with a change in control of the Company, or (iii) a change in control without any accompanying termination of employment. The amounts in the table below assume that such termination of employment and/or change in control occurred on March 31, 2018, and thus are estimates of the amounts that would be paid out to the Named Executive Officer under the circumstances. Because Ms. Schulman resigned as our Vice President, General Counsel on February 16, 2018, she was not entitled to payments or benefits in connection with her termination. See "Consulting Agreement with Ms. Schulman" for more information.

Potential Payments Upon Termination or Change in Control as of March 31, 2018

	Involuntary termination not for cause or resignation for good reason not in connection with a change in control (\$)	Involuntary termination not for cause or resignation for good reason in connection with or following a change in control (\$)	con te
Executive benefits and payments upon termination:			
Lewis Cirne			
Cash Severance	315,000	472,500	
Medical continuation	21,759	32,639	
Value of acceleration of equity awards(2)		12,552,203	
Mark Sachleben			
Cash Severance	170,000	340,000	
Medical continuation	10,880	21,759	
Value of acceleration of equity awards(2)		8,109,338	

James Gochee		
Cash Severance	167,500	335,000
Medical continuation	10,880	21,759
Value of acceleration of equity awards(2)		5,297,975

- (1) These benefits would be payable under the 2014 Plan and the 2008 Plan if, upon a Board exercised its discretion to accelerate the vesting and exercisability of outstanding awards, assuming the vesting acceleration took place on March 31, 2018. For a des

Table of Contents

of the potential vesting acceleration provisions in the 2014 Plan and the 2008 Plan, Arrangements above.

(2) The value of stock option and RSU award vesting acceleration is based on the closing price of one share of our common stock on March 29, 2018, the last trading day of fiscal 2018, the exercise price of the unvested stock option shares subject to acceleration, and the value of the stock option award that has an exercise price that exceeded the closing price of our common stock on March 29, 2018. In addition to the benefits described and quantified above, the 2014 Plan provides for an extended post-termination exercise period which an optionholder may exercise options following the optionholder's termination of employment (including the extended exercise period). Generally, under the 2014 Plan, if an optionholder's service relationship with us terminates, the optionholder may exercise any vested options for up to three months after the date that the service relationship ends. In the event of an optionholder's service relationship with us ceasing due to disability or death, the optionholder may exercise any vested options for up to 12 months in the event of disability or 18 months in the event of death after the date the service relationship ends. Accordingly, each of our Named Executive Officers has an extended post-termination exercise period in the event of a termination due to death or disability.

PAY RATIO DISCLOSURE

Under SEC rules, we are required to calculate and disclose the annual total compensation of our CEO and the ratio of the annual total compensation of our median employee as compared to the annual total compensation of our CEO (CEO Pay Ratio). To identify our median employee, we used the following methodology:

To determine our total population of employees, we included all full-time, part-time, and temporary employees, including employees of consolidated subsidiaries as of March 31, 2018.

To identify our median employee from our employee population, we calculated the annual total compensation of each employee's fiscal 2018 base pay (using hours actually worked and overtime for hourly employees and actual salary paid for our salaried employees), bonuses and other compensation for fiscal 2018 performance, and the target value of each fiscal 2018 equity award granted to our Named Executive Officers and Directors (which differs from the grant date fair value of the equity awards that we would have reported in our Summary Compensation Table with FASB Accounting Standards Codification Topic 718, *Compensation - Stock-Based Compensation* methodology used to calculate the number shares to be delivered).

In making this determination, we annualized the compensation of employees who were terminated during fiscal 2018 for less than the entire fiscal year by including each individual's target (instead of actual) compensation for the remainder of the year, including commissions, as applicable.

Compensation paid in foreign currencies was converted to U.S. dollars based on the exchange rate in effect as of March 31, 2018.

Using this approach, we determined our median employee and then calculated the annual total compensation of our median employee for fiscal 2018 in accordance with the requirements of the Summary Compensation Table.

For fiscal 2018, the median of the annual total compensation of our employees (other than our CEO) was \$100,000, compared to the annual total compensation of our CEO, as reported in the Summary Compensation Table, of \$1,000,000.

Statement, was \$3,163,466. Based on this information, the ratio of the annual total compensation of the CEO to the median of the annual total compensation of all employees was 17 to 1.

The CEO Pay Ratio above represents our reasonable estimate calculated in a manner consistent with the applicable guidance. SEC rules and guidance provide significant flexibility in how compensation is determined.

Table of Contents

median employee, and each company may use a different methodology and make different decisions than that company. As a result, and as explained by the SEC when it adopted these rules, in connection with this disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparison of compensation among different companies, even companies within the same industry, but rather to allow investors to understand and assess each particular company's compensation practices and pay ratios.

Neither the Compensation Committee nor our management used our CEO Pay Ratio methodology in making compensation decisions.

Table of Contents**DIRECTOR COMPENSATION**

The following table sets forth information regarding compensation earned by or paid to during the fiscal year ended March 31, 2018:

Fiscal 2018 Director Compensation Table

Name(1)	Fees earned or paid in cash (\$)	Stock Awards (\$)(2)	Option Awards (\$)(3)
Sohaib Abbasi	34,819	80,016	
Peter Fenton	27,339		
Sarah Friar	39,642	80,016	
Adam Messinger	33,000	80,016	
Dan Scholnick	27,946		
James Tolonen	57,321	80,016	

- (1) The aggregate number of shares of our common stock subject to outstanding stock awards held by each non-employee director listed in the table above as of March 31, 2018: (i) 11,438 shares subject to options to purchase our common stock held by Mr. Abbasi and exercisable by Mr. Abbasi as of March 31, 2018; (ii) 1,667 shares subject to a RSU award held by Mr. Abbasi as of March 31, 2018; (iii) 119,015 shares subject to options to purchase our common stock of which 115,000 were vested and exercisable by Ms. Friar as of March 31, 2018; (iv) 4,015 shares subject to an option award held by Ms. Friar as of March 31, 2018; (v) 4,015 shares subject to an option award held by Mr. Messinger, of which none were vested and exercisable by Mr. Messinger as of March 31, 2018; (vi) 40,000 shares subject to a restricted stock award held by Mr. Messinger, 834 of which were repurchased as of March 31, 2018; (vii) 1,667 shares subject to a RSU award held by Mr. Messinger as of March 31, 2018; (viii) 11,438 shares subject to options to purchase our common stock held by Mr. Tolonen, of which 10,771 were vested and exercisable by Mr. Tolonen as of March 31, 2018; and (ix) 1,667 shares subject to a RSU award held by Mr. Tolonen as of March 31, 2018.
- (2) The dollar amounts in this column reflect the aggregate grant date fair value of all RSU awards granted during fiscal 2018 computed in accordance with ASC 718 and excluding the effect of estimated forfeitures. The fair value of each RSU award is measured based on the closing price of our shares of common stock as of the date of grant. These amounts do not necessarily correspond to the actual value recognized for each non-employee director.
- (3) The dollar amounts in this column reflect the aggregate grant date fair value of all options granted during fiscal 2018 computed in accordance with ASC 718 using the Black-Scholes model and excluding the effect of estimated forfeitures. Assumptions used in the calculation of these amounts are included in our Annual Report on Form 10-K for the fiscal year ending March 31, 2018. These amounts do not necessarily correspond to the actual value recognized or that may be recognized for each non-employee director.

Our CEO does not receive additional compensation for his service on our Board. In addition, during the first quarter of fiscal 2018, we did not provide certain non-employee directors who are former or venture investor of our Company with compensation for their service on our Board. In the second quarter of fiscal 2018, we amended our non-employee director compensation policy to remove this limitation. Thus, during the second quarter of fiscal 2018, Messrs. Fenton and Scholnick became entitled to receive compensation for their service on our Board.

directors.

The Compensation Committee reviews and assesses non-employee director pay levels and its compensation consultant, Compensia. This process involves a review of competitive assessment of our director compensation policy against the director compensation program.

Table of Contents

companies in our executive compensation peer group, an update on recent trends in director compensation, and a review of best practices relating to the governance surrounding director compensation programs. Pursuant to our assessment process in August 2017, the Compensation Committee determined to amend our policy, which is set forth below.

Annual Cash Compensation

Pursuant to our non-employee director compensation policy, which was amended effective August 1, 2017, non-employee directors receive the following cash compensation for Board and Board committee service, if applicable, paid on a quarterly basis in arrears, pro-rated for any partial months of service:

\$30,000 per year for service as a Board member;

\$20,000 per year for service as the chair of the Audit Committee and \$10,000 per year for service as a member (other than as chair) of the Audit Committee;

\$15,000 per year for service as the chair of the Compensation Committee and \$7,500 per year for service as a member (other than as chair) of the Compensation Committee; and

\$6,000 per year for service as the chair of the Nominating and Corporate Governance Committee and \$3,000 per year for service as a member (other than as chair) of the Nominating and Corporate Governance Committee. For the first quarter of fiscal 2018 (prior to the amendment of our non-employee director compensation policy), the amounts paid to our non-employee directors were calculated pursuant to our non-employee director compensation policy in effect, which provided for the following:

\$30,000 per year for service as a Board member;

\$18,000 per year for service as the chair of the Audit Committee and \$9,000 per year for service as a member (other than as chair) of the Audit Committee;

\$18,000 per year for service as the chair of the Compensation Committee and \$9,000 per year for service as a member (other than as chair) of the Compensation Committee; and

\$6,000 per year for service as the chair of the Nominating and Corporate Governance Committee and \$3,000 per year for service as a member (other than as chair) of the Nominating and Corporate Governance Committee.

Equity Compensation

Pursuant to our non-employee director compensation policy, each person who is elected to be a non-employee director will automatically upon the date of his or her initial election (i) an option to purchase a number of shares of our common stock having an initial value equal to the value of the RSU award with an initial value of \$80,000, multiplied by a fraction, the numerator of which is the number of days that elapse between the non-employee director's date of initial appointment or election and the date of the grant of the Company's most recent annual grants (as discussed below) and the denominator of which is the number of days that elapse between the date of the option grant and initial RSU award will vest on August 15th following the first anniversary of the date of the Company's most recent annual grants, subject to the non-employee director's continued service to the Company.

In addition, each non-employee director will automatically, on the date of each Annual Meeting of the Board of Directors, be granted (i) an option to purchase a number of shares of our common stock having an initial value equal to the value of the RSU award with an initial value of \$80,000. Each annual grant will vest on August 15th of the year in which such annual grant is made, subject to the non-employee director's continued service to the Company. Because our non-employee director compensation policy was amended to

Table of Contents

remove the limitation on compensation to non-employee directors who may be affiliated with an investor of our Company only after our 2017 Annual Meeting of Stockholders, Messrs. [redacted] receive equity compensation during fiscal 2018.

Additionally, notwithstanding the foregoing vesting schedules, for each non-employee director in continuous service to the Company until immediately prior to the closing of a change in control (the "Change in Control") of 10% or more of the shares of our common stock subject to his or her then-outstanding equity awards that were granted under the policy will become fully vested immediately prior to the closing of such change in control.

Further, pursuant to our non-employee director compensation policy, in lieu of cash, and for each fiscal year, a non-employee director may elect to receive 100% of the annual cash compensation provided pursuant to the policy in the form of an RSU award under the 2014 Plan with a value equal to the annual cash compensation for such non-employee director for the fiscal year based on Board and Committee action on the last day of such fiscal year (the "Optional RSU Grant"). The grant date for any Optional RSU Grant occurring after the start of a fiscal year, unless such day is not a trading day on the NYSE, shall be the next trading date. The vesting commencement date for any Optional RSU Grant occurring after the start of a fiscal year. Each Optional RSU Grant will vest with respect to the units on each quarterly anniversary of the vesting commencement date for such Optional RSU Grant, provided that the non-employee director's continued service through each applicable vesting date. Optional RSU Grants are subject to accelerated vesting in connection with a change in control.

In the event a non-employee director were to become entitled to a greater annual cash compensation as a result of an increase in the cash compensation amounts approved by the Board or a new director, such non-employee director will be entitled to receive the difference paid in cash. There shall be no Optional RSU Grant in the event a non-employee director maintains continuous service but would be entitled to a lesser amount of cash compensation than that which was used to calculate the Optional RSU Grant as a result of a decrease in the cash compensation amounts approved by the Board or a decrease in the director's role).

Expense Reimbursement

We also reimburse certain non-employee directors for ordinary, necessary, and reasonable expenses incurred to cover in-person attendance at and participation in Board and Board committee meetings.

Table of Contents**EQUITY COMPENSATION PLAN INFORMATION**

The following table provides certain information with respect to all of the Company's equity compensation plans in effect as of March 31, 2018.

Plan Category	Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights(1) (a)	Weighted Average Exercise Price of Outstanding Options, Warrants and Rights(2) (b)
Equity Compensation Plans Approved By Security Holders	5,294,036(3)	\$ 22.79(4)
Equity Compensation Plans not Approved by Security Holders		
Total	5,294,036	\$ 22.79

(1) Excludes purchase rights currently outstanding under the ESPP.

(2) Excludes RSU awards because they have no exercise price.

(3) The number in this column consists of: (i) 2,111,083 shares to be issued upon the exercise of outstanding options and 85,043 shares to be issued pursuant to the vesting of outstanding RSU awards that were in effect under the 2008 Plan and (ii) 1,104,281 shares to be issued upon the exercise of outstanding options and 85,043 shares to be issued pursuant to the vesting of outstanding RSU awards that were in effect under the 2014 Plan.

(4) The weighted average exercise price of outstanding options granted under the 2008 Plan is \$22.79 and the weighted average exercise price of outstanding options granted under the 2014 Plan is \$22.79.

(5) No shares remain available for future issuance under the 2008 Plan. We ceased granting awards under the 2008 Plan when our 2014 Plan became effective on December 11, 2014. However, any awards granted under the 2008 Plan remain outstanding, subject to the terms of the award agreements, until such outstanding awards are exercised or vest, or until they terminate.

(6) As of March 31, 2018, 9,575,959 shares were available for future issuance under the 2014 Plan. Pursuant to the terms of the 2014 Plan, on April 1 of each year, commencing on April 1, 2014, and ending on April 1, 2024, the number of shares authorized for issuance under the 2014 Plan is a number equal to: (i) 5% of the total number of shares of capital stock outstanding on the last day of the preceding calendar year; or (ii) such lesser number of shares of common stock as is determined by the Compensation Committee for the applicable year. Pursuant to the previously described terms, the number of shares available under the 2014 Plan was increased by 2,355,847 shares, on April 1, 2018, and the number of shares available under the 2014 Plan was increased by 2,499,059 shares, on April 1, 2019.

- available under the 2014 Plan was increased by 2,663,972 shares, and on April 1, 2015, the number of shares available under the 2014 Plan was increased by 2,797,664 shares.
- (7) As of March 31, 2018, 1,929,237 shares were available for future issuance under the ESPP, which became effective on December 11, 2014. Initially, the ESPP authorized the issuance of 1,000,000 shares of common stock pursuant to purchase rights granted to our employees or to employees of any subsidiary of our company. Pursuant to the terms of the ESPP, on April 1 of each year, commencing on April 1, 2015, the number of shares authorized for issuance under the ESPP is automatically increased by the lesser of: (i) 500,000 shares of our common stock; (ii) 1% of the total number of shares of our common stock outstanding on March 31 of the preceding calendar year; or (iii) such lesser number of shares as may be determined by the Board or the Compensation Committee for the applicable year. Pursuant to the described terms, on April 1, 2015, the number

Table of Contents

of shares available under the ESPP was increased by 471,169 shares, on April 1, 2016, the number of shares available under the ESPP was increased by 499,811 shares, on April 1, 2017, the number of shares available under the ESPP was increased by 500,000 shares, and on April 1, 2018, the number of shares available under the ESPP was increased by 500,000 shares. The maximum aggregate number of shares of our common stock that may be purchased by all participants in the ESPP during any current purchase period is 500,000 shares, the number of shares as are available for issuance under the ESPP.

Table of Contents

TRANSACTIONS WITH RELATED PERSONS

Since April 1, 2017, there has not been nor is there currently proposed any transaction of which we were or are to be a party in which the amount involved exceeds \$120,000 and officer, holder of more than 5% of our common stock, or any member of the immediate persons, had or will have a direct or indirect material interest, other than compensation arrangements described elsewhere in this Proxy Statement.

INVESTOR RIGHTS AGREEMENT

In April 2014, we entered into an Amended and Restated Investor Rights Agreement, with rights agreement, with certain holders of our then-outstanding convertible preferred stock with each of Benchmark and Trinity Ventures, which our directors Peter Fenton and Dan affiliated. Such holders party to our investor rights agreement, as well as certain affiliate have rights, subject to certain conditions, to require us to file registration statements covered in registration statements that we may file for ourselves or our stockholders.

INDEMNIFICATION AGREEMENTS

Our amended and restated certificate of incorporation and amended and restated bylaws our directors and officers, and may indemnify our employees and other agents, to the full Delaware General Corporation Law. In addition, we have entered into indemnification agreements with our current directors, executive officers, and some of our employees. These agreements provide such persons for all reasonable expenses and liabilities incurred in connection with any action against them by reason of the fact that they are or were serving in such capacity. We have liability insurance to cover liabilities our directors and officers may incur in connection

POLICIES AND PROCEDURES FOR TRANSACTIONS WITH RELATED PERSONS

We have adopted a policy that our executive officers, directors, nominees for election as more than 5% of any class of our common stock, and any members of the immediate family persons are not permitted to enter into a related person transaction with us without the approval of the Audit Committee. Any request for us to enter into a transaction with an executive officer, director, beneficial owner of more than 5% of any class of our common stock, or any member of any of the foregoing persons, in which the amount involved exceeds \$100,000 and such person has a direct or indirect interest, must be presented to our Audit Committee for review, consideration, and approval. In approving or rejecting any such proposal, our Audit Committee is to consider the materiality of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than those that would be available to an unaffiliated third party under the same or similar circumstances and the extent of the related person's interest in the transaction. All of the transactions described above were presented, considered, and approved by the Audit Committee.

Table of Contents

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to send Notices of Internet Availability of Proxy Materials or other Annual Meeting materials to stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly known as householding, potentially means extra convenience for stockholders and cost savings for the Company.

This year, a number of brokers with account holders who are New Relic stockholders will be delivering a single Notice of Internet Availability of Proxy Materials to all of the Company's proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to all stockholders sharing an address unless contrary instructions have been received from the stockholder. If you have received notice from us (if you are a stockholder of record) or from your broker, you consent that we or they will be householding communications to your address, householding communications to you otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding, you prefer to receive a separate Notice of Internet Availability of Proxy Materials, or if you are a stockholder of record and would like to request householding of your communications, please notify your broker or contact our Corporate Secretary in a written request to the Company to our Corporate Secretary at New Relic, Inc., 188 Spear Street, San Francisco, California 94105, or contact our Corporate Secretary at (650) 777-7600. In accordance with the instructions, we will deliver, upon written or oral request to the address or telephone number above, a separate Notice of Internet Availability of Proxy Materials or other Annual Meeting materials, as applicable, to a stockholder to which a single copy of the documents was delivered.

OTHER MATTERS

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If other matters are properly brought before the meeting, it is the intention of the persons named in the proxy to vote on such matters in accordance with their best judgment.

By Order of the Board of Directors

/s/ Mark Sachleben

Mark Sachleben

Chief Financial Officer and Corporate Secretary

July 11, 2018

A copy of the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2018, is available without charge upon written request to: Corporate Secretary, New Relic, Inc., 188 Spear Street, San Francisco, California 94105.

**THIS PROXY CARD IS VALID ONLY WHEN SIGNED DETACH AND RE
AND DATED.**

NEW RELIC, INC.

The Board of Directors recommends you vote FOR the following:

1. Election of Directors

Nominees:

- 01) Sohaib Abbasi
- 02) Hope Cochran
- 03) Adam Messinger

To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below.

The Board of Directors recommends you vote FOR the following proposal:

2. To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

The Board of Directors recommends you vote FOR the following proposal:

3. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending March 31, 2019.

NOTE: In their discretion, the proxyholders are authorized to vote upon such other business as may properly come before the meeting and any adjournment or postponement thereof.

In the event of a change of address, please check this box and write the new address on the back where indicated.

Please indicate if you plan to attend this meeting.

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each

personally. All holders must sign. If a corporation or partnership, please sign in full c
partnership name by authorized officer.

Signature [PLEASE SIGN WITHIN BOX]

Date

Signature (Joint Owners)

Date

Table of Contents

Important Notice Regarding the Availability of Proxy Materials for the

The Annual Report on Form 10-K and the Notice and Proxy Statement for the 2018

Annual Meeting of Stockholders are available at www.proxyvote.com.

NEW RELIC, INC.

Annual Meeting of Stockholders

August 21, 2018 9:00 AM Local Time

This Proxy is solicited on behalf of the Board of Directors

The undersigned stockholder of New Relic, Inc. hereby acknowledges receipt of the Annual Report on Form 10-K and the Notice and Proxy Statement for the 2018 Annual Meeting and hereby appoints Lewis and Clark LLP, either of them, as proxies and attorneys-in-fact, each with full power of substitution, on behalf of the undersigned, to represent the undersigned at the 2018 Annual Meeting of Stockholders of New Relic, Inc. on Tuesday, August 21, 2018 at 9:00 a.m. local time at the offices of Cooley LLP, 101 California Street, San Francisco, California 94111, and at any adjournments thereof, and to vote all shares of common stock of New Relic, Inc. that the undersigned would be entitled to vote if then and there personally present, on the matters to be voted on at the meeting.

THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTIONS ARE SPECIFIED, THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE BOARD OF DIRECTORS' RESOLUTIONS AND WITH RESPECT TO SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF, AS SAID PROXIES DEEM ADVISABLE.

Address Change:

(If you noted an address change above, please mark corresponding box on

Continued and to be signed on reverse side